🟢 CLPT is trading 5.8% up today on continued momentum from uniQure Huntington’s therapy progress

CLPT is trading 5.8% up at $18.50 in pre-market, extending gains driven by its partnership with uniQure on a Huntington’s disease gene therapy.

• The strength is linked to uniQure’s AMT-130 program, which employs ClearPoint’s specialized navigation system and SmartFlow cannula.
• A recent major FDA pathway development for the therapy previously triggered a 50% surge in CLPT, significantly strengthening the stock's bull case.
• Ongoing regulatory momentum and positive investor sentiment surrounding the partnership continue to drive the current price action.